-
Mashup Score: 3Survey Finds Sexuality and Fertility Discussions Remain Sidelined Among Young Patients Diagnosed With Breast Cancer - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 12/11/2022 10:00:00 AM Last Updated: 12/11/2022 7:32:38 AM In a new survey, a majority (64%) of patients diagnosed with breast cancer younger than 46 years reported significant impacts to their sexual health, yet 86% of patients reported that their health-care provider was…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 12/10/2022 10:00:00 AM Last Updated: 12/10/2022 2:59:28 PM Patients with multiple tumors in a single breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post - 1 year(s) ago
By Alice Goodman Posted: 12/10/2022 11:53:00 AM Last Updated: 12/10/2022 2:48:41 PM Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Impact on Cognitive Function of Adding Chemotherapy to Endocrine Therapy for Breast Cancer - The ASCO Post - 1 year(s) ago
By Alice Goodman Posted: 12/10/2022 10:00:00 AM Last Updated: 12/10/2022 11:16:55 AM Chemotherapy followed by endocrine therapy led to more cancer-related cognitive impairment compared with endocrine therapy alone in patients with hormone receptor–positive, HER2-negative breast cancer at 36 months, according…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Expert Discusses Breast Conservation Therapy’s Impact on Recurrence for Multiple Ipsilateral Breast Cancer - 1 year(s) ago
Patients with multiple ipsilateral breast cancer might benefit from having a preoperative MRI before proceeding with breast conservation therapy, according to Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Joannie Ivory and Lisa Carey on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer - The ASCO Post - 1 year(s) ago
2022 San Antonio Breast Cancer Symposium Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Improved Survival Benefit With the Use of Circulating Tumor Count Application in First-Line Metastatic Breast Cancer - 1 year(s) ago
Results from the phase 3 STIC CTC trial found an improved overall survival when circulating tumor cells were used as a guide in combination with chemotherapy or endocrine therapy in patients with hormone receptor–positive/HER2-negative breast cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Mariana Chavez-MacGregor on Adjuvant Endocrine Therapy and Everolimus in HR-Positive HER2-Negative Breast Cancer - The ASCO Post - 1 year(s) ago
2022 San Antonio Breast Cancer Symposium Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone receptor–positive, HER2-negative early-stage…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr Jose P. Leone Highlights the Importance of Breast Cancer Awareness for Male Patients - 1 year(s) ago
Jose P. Leone, MD, director of the program for breast cancer in men at the Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, shares why patients and providers need to pay more attention to how breast cancer impacts male patients.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Adding Palbociclib to Fulvestrant Did Not Yield Better Efficacy in ER-positive/HER2-Negative Metastatic Breast Cancer - 1 year(s) ago
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Survey Finds Sexuality and Fertility Discussions Remain Sidelined Among Young Patients Diagnosed With Breast Cancer https://t.co/tSftnbprRT #SABCS22 #SABCS2022 #bcsm #breastcancer #oncology @SABCSSanAntonio